Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination

Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination

SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and se...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Future oncology (London, England) England), 2022-07, Vol.18 (23), p.2537-2550
Hauptverfasser: Janzic, Urska, Bidovec-Stojkovic, Urska, Mohorcic, Katja, Mrak, Loredana, Dovnik, Nina Fokter, Ivanovic, Marija, Ravnik, Maja, Caks, Marina, Skof, Erik, Debeljak, Jerneja, Korosec, Peter, Rijavec, Matija
Format: Artikel
Sprache:eng
Schlagworte:
anticancer treatment
immunogenicity
mRNA-based vaccination
seroconversion
solid cancer
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p 
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2022-0148